Currently, RNT with [177Lu]Lu‐PSMA‐617 is mainly provided to patients with metastastic castration‐resistant prostate cancer post taxane and one novel‐generation androgen‐axis targeting drug with a high tumour burden (Kratochwil et al., 2023), i.e. not to the patient population described in this study. Here, FOLH1 is linked to neoplasm.